RBC Capital raised its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $98.00 (from $91.00) while maintaining an Outperform rating.Analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View Analyst PT Change

Sarepta Therapeutics (SRPT) PT Raised to $96 at H.C. WainwrightMay 7, 2018 8:17 AM Sarepta Therapeutics (SRPT) PT Raised to $109 at Needham & CompanyMay 7, 2018 6:20 AM Sarepta Therapeutics (SRPT) PT Lowered to $90 at H.C. WainwrightMay 4, 2018 7:14 AM Sarepta Therapeutics' (SRPT) In Line Quarter Shifts Focus To R&D DayMay 4, 2018 7:01 AM Sarepta Therapeutics (SRPT) PT Raised to $91 at Morgan StanleyMay 4, 2018 6:44 AM Sarepta Therapeutics (SRPT): R&D Day Should Reveal Gene Therapy Data - BairdMay 4, 2018 6:43 AM Oppenheimer Downgrades Sarepta Therapeutics (SRPT) to PerformMay 4, 2018 5:31 AM Sarepta Therapeutics (SRPT) PT Lowered to $90 at JMP SecuritiesMay 4, 2018 4:08 AM Oppenheimer Downgrades Sarepta Therapeutics (SRPT) to PerformMay 4, 2018 2:37 AM Sarepta Therapeutics (SRPT) Tops Q1 EPS by 4cMay 3, 2018 4:05 PM Sarepta Therapeutics Announces Partnership with Myonexus Therapeutics for the Advancement of Multiple Gene Therapy Programs Aimed at Treating Distinct Forms of Limb-Girdle Muscular DystrophiesMay 3, 2018 4:01 PM